Effectiveness of add-on therapy with domperidone vs alginic acid in proton pump inhibitor partial response gastro-oesophageal reflux disease in systemic sclerosis: Randomized placebo-controlled trial

Rheumatology (United Kingdom)

Volumn 56, Issue 2, 2017, Pages 214-222

  Foocharoen, Chingching ^a   Chunlertrith, Kitti ^a   Mairiang, Pisaln ^a   Mahakkanukrauh, Ajanee ^a   Suwannaroj, Siraphop ^a   Namvijit, Suwassa ^a   Wantha, Orathai ^a   Nanagara, Ratanavadee ^a  

^a KHON KAEN UNIVERSITY   (Thailand)

Author keywords

Clinical trials and methods; Gastrointestinal; Outcome measures; Quality of life; Scleroderma related disorder

Indexed keywords

ALGYCON; ANTACID AGENT; ANTIBIOTIC AGENT; DOMPERIDONE; OMEPRAZOLE; PLACEBO; UNCLASSIFIED DRUG; ALGINIC ACID; ANTIEMETIC AGENT; GLUCURONIC ACID; HEXURONIC ACID; PROTON PUMP INHIBITOR;

ADD ON THERAPY; ADULT; ANTIBIOTIC THERAPY; ARTICLE; CHRONOPHARMACOLOGY; COMBINATION DRUG THERAPY; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DIGESTIVE SYSTEM DISEASE ASSESSMENT; DISEASE SEVERITY; DISEASE SEVERITY ASSESSMENT; DOSE RESPONSE; DRUG CONTAMINATION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; EUROQOL FIVE DIMENSIONS QUESTIONNAIRE; FATIGUE; FEASIBILITY STUDY; FEMALE; FINGER ULCER; FOLLOW UP; FREQUENCY SCALE FOR SYMPTOMS OF GASTROESOPHAGEAL REFLUX; GASTROESOPHAGEAL REFLUX; HEART ARRHYTHMIA; HEARTBURN; HUMAN; INTERVENTION STUDY; LEG PAIN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NAUSEA; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; QUALITY OF LIFE ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; SKIN CALCIFICATION; SKIN INFECTION; SYSTEMIC SCLEROSIS; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VISUAL ANALOG SCALE; AGED; COMPARATIVE STUDY; COMPLICATION;

ADULT; AGED; ALGINATES; ANTIEMETICS; DOMPERIDONE; DRUG THERAPY, COMBINATION; FEMALE; GASTROESOPHAGEAL REFLUX; GLUCURONIC ACID; HEXURONIC ACIDS; HUMANS; MALE; MIDDLE AGED; OMEPRAZOLE; PROTON PUMP INHIBITORS; SCLERODERMA, SYSTEMIC; TREATMENT OUTCOME;

EID: 85039809836     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kew216     Document Type: Article

References (38)

1. LeRoy EC, Black C, Fleischmajer R et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988;15:202-5.
2. Steen VD, Medsger TA Jr. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 2000;43:2437-44.
3. Ebert EC. Gastric and enteric involvement in progressive systemic sclerosis. J Clin Gastroenterol 2008;42:5-12.
4. Panicheewa S, Chitrabamrung S, Verasertniyom O et al. Diffuse systemic sclerosis and related diseases in Thailand. Clin Rheumatol 1991;10:124-9.
5. Ntoumazios SK, Voulgari PV, Potsis K et al. Esophageal involvement in scleroderma: gastroesophageal reflux, the common problem. Semin Arthritis Rheum 2006;36:173-81.
6. Ebert EC. Esophageal disease in scleroderma. J Clin Gastroenterol 2006;40:769-75.
7. Forbes A, Marie I. Gastrointestinal complications: the most frequent internal complications of systemic sclerosis. Rheumatology 2009;48(Suppl 3):iii36-9.
8. Lacy BE, Weiser K, Chertoff J et al. The diagnosis of gastroesophageal reflux disease. Am J Med 2010;123:583-92.
9. Tiev KP, Cabane J. Digestive tract involvement in systemic sclerosis. Autoimmun Rev 2011;11:68-73.
10. Christmann RB, Wells AU, Silver RM. Gastroesophageal reflux incites interstitial lung disease in systemic sclerosis: clinical, radiologic, histopathologic, and treatment evidence. Semin Arthritis Rheum 2010;40:241-49
11. Lock G, Zeuner M, Lang B et al. Anorectal function in systemic sclerosis: correlation with esophageal dysfunction? Dis Colon Rectum 1997;40:1328-35.
12. Armstrong D, Marshall JK, Chiba N et al. Canadian Consensus Conference on the management of gastroesophageal reflux disease in adults-update 2004. Can J Gastroenterol 2005;19:15-35.
13. DeVault KR, Castell DO. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol 2005;100:190-200.
14. Kahrilas PJ. Clinical practice. Gastroesophageal reflux disease. N Engl J Med 2008;359:1700-7.
15. Moraes-Filho JPP, Navarro-Rodriguez T, Barbuti R et al. Guidelines for the diagnosis and management of gastroesophageal reflux disease: an evidence-based consensus. Arq Gastroenterol 2010;47:99-115.
16. Khanna D, Nagaraja V, Gladue H et al. Measuring response in the gastrointestinal tract in systemic sclerosis. Curr Opin Rheumatol 2013;25:700-6.
17. Chunlertrith K, Noiprasit A, Foocharoen C et al. GERD questionnaire for diagnosis of gastroesophageal reflux disease in systemic sclerosis. Clin Exp Rheumatol 2014;32:S-98-102.
18. Hansi N, Thoua N, Carulli M et al. Consensus best practice pathway of the UK scleroderma study group: gastrointestinal manifestations of systemic sclerosis. Clin Exp Rheumatol 2014;32: S-214-21.
19. Ramirez-Mata M, Ibañez G, Alarcon-Segovia D. Stimulatory effect of metoclopramide on the esophagus and lower esophageal sphincter of patients of patients with PSS. Arthritis Rheum 1977;20:30-4.
20. Kowal-Bielecka O, Landewé R, Avouac J et al. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis 2009;68:620-8.
21. Walker KM, Pope J. Treatment of systemic sclerosis complications: what to use when first-line treatment fails-a consensus of systemic sclerosis experts. Semin Arthritis Rheum 2012;42:42-55
22. Stanciu C, Bennett JR. Alginate-antacid in the reduction of gastro-oesophageal reflux. Lancet 1974;1:109-11.
23. Malmud LS, Charkes ND, Littlefield J et al. The mode of action alginic acid compound in the reduction of gastroesophageal reflux. J Nucl Med 1979;20:1023-8.
24. Lai I-R, Wu M-S, Lin J-T. Prospective, randomized, and active controlled study of the efficacy of alginic acid and antacid in the treatment of patients with endoscopynegative reflux disease. World J Gastroenterol 2006;12:747-54.
25. Combination of cimetidine and alginic acid: an improvement in the treatment of oesophageal reflux disease. Cooperative Oesophageal Group. Gut 1991;32:819-22.
26. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980;23:581-90.
27. Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol 2006;101:1900-20; quiz 1943.
28. Mandel KG, Daggy BP, Brodie DA, Jacoby HI. Review article: alginate-raft formulations in the treatment of heartburn and acid reflux. Aliment Pharmacol Ther 2000;14:669-90.
29. Bredenoord AJ, Smout AJ. Refractory gastrooesophageal reflux disease. Eur J Gastroenterol Hepatol 2008;20:217-23.
30. Furuta T, Shimatani T, Sugimoto M et al. Investigation of pretreatment prediction of proton pump inhibitor (PPI)-resistant patients with gastroesophageal reflux disease and the dose escalation challenge of PPIs-TORNADO study: a multicenter prospective study by the Acid-Related Symptom Research Group in Japan. J Gastroenterol 2011;46:1273-83.
31. Sugimoto M, Nishino M, Kodaira C et al. Characteristics of non-erosive gastroesophageal reflux disease refractory to proton pump inhibitor therapy. World J Gastroenterol 2011;17:1858-65.
32. Johannes CB, Varas-Lorenzo C, McQuay LJ, Midkiff KD, Fife D. Risk of serious ventricular arrhythmia and sudden cardiac death in a cohort of users of domperidone: a nested case-control study. Pharmacoepidemiol Drug Saf 2010;19:881-8.
33. Kanji S, Stevenson A, Hutton B. Sudden cardiac death and ventricular arrhythmias associated with domperidone: evidence supporting health Canada's warning. Can J Hosp Pharm 2014;67:311-2.
34. Thonhofer R, Siegel C, Trummer M, Graninger W. Early endoscopy in systemic sclerosis without gastrointestinal symptoms. Rheumatol Int 2012;32:165-8.
35. Miyamoto M, Haruma K, Takeuchi K, Kuwabara M. Frequency scale for symptoms of gastroesophageal reflux disease predicts the need for addition of prokinetics to proton pump inhibitor therapy. J Gastroenterol Hepatol 2008;23:746-51.
36. Fass R. Proton pump inhibitor failure-what are the therapeutic options? Am J Gastroenterol 2009;104(Suppl 2):S33-8.
37. Fackler WK, Ours TM, Vaezi MF, Richter JE. Long-term effect of H2RA therapy on nocturnal gastric acid breakthrough. Gastroenterology 2002;122:625-32.
38. Peek RM. Helicobacter pylori and gastroesophageal reflux disease. Curr Treat Options Gastroenterol 2004;7:59-70.